Literature DB >> 34017677

A property-response perspective on modern toxicity assessment and drug toxicity index (DTI).

Vaibhav A Dixit1, Pragati Singh1.   

Abstract

Toxicity related failures in drug discovery and clinical development have motivated scientists and regulators to develop a wide range of in-vitro, in-silico tools coupled with data science methods. Older drug discovery rules are being constantly modified to churn out any hidden predictive value. Nonetheless, the dose-response concepts remain central to all these methods. Over the last 2 decades medicinal chemists, and pharmacologists have observed that different physicochemical, and pharmacological properties capture trends in toxic responses. We propose that these observations should be viewed in a comprehensive property-response framework where dose is only a factor that modifies the inherent toxicity potential. We then introduce the recently proposed "Drug Toxicity Index (DTI)" and briefly summarize its applications. A webserver is available to calculate DTI values (https://all-tool-kit.github.io/Web-Tool.html).
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.

Entities:  

Keywords:  drug-like molecular space; pharmacokinetic properties; pharmacodynamic properties; physicochemical properties

Year:  2021        PMID: 34017677      PMCID: PMC8124026          DOI: 10.1007/s40203-021-00096-9

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  36 in total

Review 1.  Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment.

Authors:  Gerald T Ankley; Richard S Bennett; Russell J Erickson; Dale J Hoff; Michael W Hornung; Rodney D Johnson; David R Mount; John W Nichols; Christine L Russom; Patricia K Schmieder; Jose A Serrrano; Joseph E Tietge; Daniel L Villeneuve
Journal:  Environ Toxicol Chem       Date:  2010-03       Impact factor: 3.742

2.  Physiochemical drug properties associated with in vivo toxicological outcomes.

Authors:  Jason D Hughes; Julian Blagg; David A Price; Simon Bailey; Gary A Decrescenzo; Rajesh V Devraj; Edmund Ellsworth; Yvette M Fobian; Michael E Gibbs; Richard W Gilles; Nigel Greene; Enoch Huang; Teresa Krieger-Burke; Jens Loesel; Travis Wager; Larry Whiteley; Yao Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-07-24       Impact factor: 2.823

Review 3.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

Review 4.  The role of ligand efficiency metrics in drug discovery.

Authors:  Andrew L Hopkins; György M Keserü; Paul D Leeson; David C Rees; Charles H Reynolds
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

5.  Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential.

Authors:  Michael D Aleo; Falgun Shah; Scott Allen; Hugh A Barton; Chester Costales; Sarah Lazzaro; Louis Leung; Andrea Nilson; R Scott Obach; A David Rodrigues; Yvonne Will
Journal:  Chem Res Toxicol       Date:  2019-10-07       Impact factor: 3.739

Review 6.  A practical guide to secondary pharmacology in drug discovery.

Authors:  Stephen Jenkinson; Friedemann Schmidt; Lyn Rosenbrier Ribeiro; Annie Delaunois; Jean-Pierre Valentin
Journal:  J Pharmacol Toxicol Methods       Date:  2020-04-14       Impact factor: 1.950

Review 7.  Rethinking drug design in the artificial intelligence era.

Authors:  Petra Schneider; W Patrick Walters; Alleyn T Plowright; Norman Sieroka; Jennifer Listgarten; Robert A Goodnow; Jasmin Fisher; Johanna M Jansen; José S Duca; Thomas S Rush; Matthias Zentgraf; John Edward Hill; Elizabeth Krutoholow; Matthias Kohler; Jeff Blaney; Kimito Funatsu; Chris Luebkemann; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2019-12-04       Impact factor: 84.694

8.  Value of shared preclinical safety studies - The eTOX database.

Authors:  Katharine Briggs; Chris Barber; Montserrat Cases; Philippe Marc; Thomas Steger-Hartmann
Journal:  Toxicol Rep       Date:  2014-12-18

Review 9.  Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.

Authors:  Sabina Halappanavar; Sybille van den Brule; Penny Nymark; Laurent Gaté; Carole Seidel; Sarah Valentino; Vadim Zhernovkov; Pernille Høgh Danielsen; Andrea De Vizcaya; Henrik Wolff; Tobias Stöger; Andrey Boyadziev; Sarah Søs Poulsen; Jorid Birkelund Sørli; Ulla Vogel
Journal:  Part Fibre Toxicol       Date:  2020-05-25       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.